CN112567049A - 鉴定胃癌状态的方法和试剂盒 - Google Patents
鉴定胃癌状态的方法和试剂盒 Download PDFInfo
- Publication number
- CN112567049A CN112567049A CN201880095978.7A CN201880095978A CN112567049A CN 112567049 A CN112567049 A CN 112567049A CN 201880095978 A CN201880095978 A CN 201880095978A CN 112567049 A CN112567049 A CN 112567049A
- Authority
- CN
- China
- Prior art keywords
- seq
- sequence
- sequence shown
- gene
- primer pair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims abstract description 146
- 206010017758 gastric cancer Diseases 0.000 title claims abstract description 142
- 201000011549 stomach cancer Diseases 0.000 title claims abstract description 142
- 238000000034 method Methods 0.000 title claims abstract description 60
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 181
- 230000011987 methylation Effects 0.000 claims abstract description 166
- 238000007069 methylation reaction Methods 0.000 claims abstract description 166
- 239000000090 biomarker Substances 0.000 claims abstract description 96
- 239000012472 biological sample Substances 0.000 claims abstract description 85
- 101150042012 SEPTIN9 gene Proteins 0.000 claims abstract description 49
- 102000012060 Septin 9 Human genes 0.000 claims abstract description 49
- 102100039798 E3 ubiquitin-protein ligase RNF180 Human genes 0.000 claims abstract description 47
- 101000667651 Homo sapiens E3 ubiquitin-protein ligase RNF180 Proteins 0.000 claims abstract description 46
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 claims abstract description 42
- 101000692109 Homo sapiens Syndecan-2 Proteins 0.000 claims abstract description 42
- 102100026087 Syndecan-2 Human genes 0.000 claims abstract description 42
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 claims abstract description 40
- 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 claims abstract description 39
- 102100037504 Paired box protein Pax-5 Human genes 0.000 claims abstract description 39
- 108010079362 Core Binding Factor Alpha 3 Subunit Proteins 0.000 claims abstract description 38
- 102000012666 Core Binding Factor Alpha 3 Subunit Human genes 0.000 claims abstract description 38
- 108010048992 Transcription Factor 4 Proteins 0.000 claims abstract description 20
- 102000009523 Transcription Factor 4 Human genes 0.000 claims abstract description 19
- 101000956145 Homo sapiens Death-associated protein kinase 1 Proteins 0.000 claims abstract 18
- 102100038587 Death-associated protein kinase 1 Human genes 0.000 claims abstract 12
- 230000000903 blocking effect Effects 0.000 claims description 108
- 239000000523 sample Substances 0.000 claims description 99
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 96
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 94
- 229920001184 polypeptide Polymers 0.000 claims description 92
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 92
- 238000001514 detection method Methods 0.000 claims description 88
- 238000006243 chemical reaction Methods 0.000 claims description 76
- 238000012408 PCR amplification Methods 0.000 claims description 74
- 239000012634 fragment Substances 0.000 claims description 68
- 108020004414 DNA Proteins 0.000 claims description 58
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 150000007523 nucleic acids Chemical class 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 26
- 102000039446 nucleic acids Human genes 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 24
- -1 RASSF1A Proteins 0.000 claims description 23
- 101000976959 Homo sapiens Transcription factor 4 Proteins 0.000 claims description 20
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 claims description 20
- 238000007477 logistic regression Methods 0.000 claims description 18
- 230000003321 amplification Effects 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 17
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 17
- 101150083915 cdh1 gene Proteins 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 210000002381 plasma Anatomy 0.000 claims description 13
- 101100351019 Homo sapiens PAX5 gene Proteins 0.000 claims description 12
- 101100476219 Homo sapiens RUNX3 gene Proteins 0.000 claims description 12
- 101150017484 PAX5 gene Proteins 0.000 claims description 12
- 101150032258 RNF180 gene Proteins 0.000 claims description 12
- 108050002584 Septin 9 Proteins 0.000 claims description 12
- 101150017815 TCF4 gene Proteins 0.000 claims description 12
- 102100023489 Transcription factor 4 Human genes 0.000 claims description 12
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 12
- 101150118392 sdc-2 gene Proteins 0.000 claims description 12
- 238000007400 DNA extraction Methods 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical group [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 208000009956 adenocarcinoma Diseases 0.000 claims description 7
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 7
- 238000001574 biopsy Methods 0.000 claims description 6
- 201000010879 mucinous adenocarcinoma Diseases 0.000 claims description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000005259 measurement Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 101150087690 ACTB gene Proteins 0.000 claims description 4
- 206010003445 Ascites Diseases 0.000 claims description 4
- 101100256304 Caenorhabditis elegans sdc-2 gene Proteins 0.000 claims description 4
- 206010017763 Gastric cancer stage I Diseases 0.000 claims description 4
- 206010017764 Gastric cancer stage II Diseases 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 210000002751 lymph Anatomy 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 238000010791 quenching Methods 0.000 claims description 3
- 230000000171 quenching effect Effects 0.000 claims description 3
- 238000011191 terminal modification Methods 0.000 claims description 3
- 238000010923 batch production Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 23
- 239000011324 bead Substances 0.000 description 20
- 239000003550 marker Substances 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 201000010099 disease Diseases 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 12
- 239000011534 wash buffer Substances 0.000 description 12
- 239000007853 buffer solution Substances 0.000 description 11
- 239000006174 pH buffer Substances 0.000 description 11
- 239000006148 magnetic separator Substances 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 229940122426 Nuclease inhibitor Drugs 0.000 description 8
- 238000004140 cleaning Methods 0.000 description 8
- 239000003398 denaturant Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000007067 DNA methylation Effects 0.000 description 6
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 239000012149 elution buffer Substances 0.000 description 6
- 238000003908 quality control method Methods 0.000 description 6
- 239000012148 binding buffer Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000012139 lysis buffer Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000010414 supernatant solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091029523 CpG island Proteins 0.000 description 3
- 208000012895 Gastric disease Diseases 0.000 description 3
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 201000011591 microinvasive gastric cancer Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000001839 endoscopy Methods 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- AOSFMYBATFLTAQ-UHFFFAOYSA-N 1-amino-3-(benzimidazol-1-yl)propan-2-ol Chemical compound C1=CC=C2N(CC(O)CN)C=NC2=C1 AOSFMYBATFLTAQ-UHFFFAOYSA-N 0.000 description 1
- BRRSNXCXLSVPFC-UHFFFAOYSA-N 2,3,4-Trihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1O BRRSNXCXLSVPFC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 230000026641 DNA hypermethylation Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- PQUCIEFHOVEZAU-UHFFFAOYSA-N Diammonium sulfite Chemical compound [NH4+].[NH4+].[O-]S([O-])=O PQUCIEFHOVEZAU-UHFFFAOYSA-N 0.000 description 1
- 101001031598 Dictyostelium discoideum Probable serine/threonine-protein kinase fhkC Proteins 0.000 description 1
- 101710157258 E3 ubiquitin-protein ligase RNF180 Proteins 0.000 description 1
- 206010017817 Gastric polyps Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000009184 Neoplasms by Histologic Type Diseases 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 108010048999 Transcription Factor 3 Proteins 0.000 description 1
- 102100038313 Transcription factor E2-alpha Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013398 bayesian method Methods 0.000 description 1
- 238000001369 bisulfite sequencing Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000014200 hypermethylation of CpG island Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000007855 methylation-specific PCR Methods 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 150000005430 trihydroxybenzoic acid derivatives Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
一种在受试者中鉴定胃癌状态的方法，包括：1)从所述受试者采集生物样品；2)检测所述生物样品中生物标志物基因的甲基化水平，其中所述生物标志物基因选自如下基因的一种或多种：CDH1、DAPK、PAX5、RASSF1A、Reprimo、RNF180、RUNX3、SDC2、Septin9和TCF4；以及3)将步骤2)检测的甲基化水平与群体中相应生物标志物基因的正常甲基化水平进行比较，以确定所述受试者中的胃癌状态。还提供了用于鉴定受试者中胃癌状态的试剂盒。所提供的方法和试剂盒为胃癌的预测、诊断、和评估提供了一条快速、可靠、准确的新途径。
Description
PCT国内申请，说明书已公开。
Claims (36)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/097297 WO2020019269A1 (zh) | 2018-07-26 | 2018-07-26 | 鉴定胃癌状态的方法和试剂盒 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112567049A true CN112567049A (zh) | 2021-03-26 |
Family
ID=69182140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880095978.7A Pending CN112567049A (zh) | 2018-07-26 | 2018-07-26 | 鉴定胃癌状态的方法和试剂盒 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20210222260A1 (zh) |
| EP (1) | EP3828289A4 (zh) |
| CN (1) | CN112567049A (zh) |
| WO (1) | WO2020019269A1 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113186282A (zh) * | 2021-04-29 | 2021-07-30 | 北京艾克伦医疗科技有限公司 | 鉴定胰腺癌状态的方法和试剂盒 |
| CN113355416A (zh) * | 2021-06-04 | 2021-09-07 | 杭州圣庭医疗科技有限公司 | 一种用于检测胃癌相关基因甲基化的核酸组合物、试剂盒和检测方法 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111549129B (zh) * | 2020-03-30 | 2023-08-29 | 宁波美康盛德医学检验所有限公司 | 用于检测胃癌的试剂盒及其应用 |
| WO2022035206A1 (ko) * | 2020-08-11 | 2022-02-17 | 서울대학교병원 | Dna 메틸화 수준 검출 제제를 포함하는 위암 예측 또는 진단용 조성물 |
| NL2027228B1 (en) * | 2020-12-24 | 2022-07-20 | Stichting Vumc | Detection of nucleic acid markers in urine using DNA methylation analysis |
| CN113234821B (zh) * | 2021-04-29 | 2022-09-16 | 北京艾克伦医疗科技有限公司 | 鉴定食管癌状态的方法和试剂盒 |
| CN114574560A (zh) * | 2022-04-21 | 2022-06-03 | 上海长岛抗体诊断试剂有限公司 | 一种快速dna亚硫酸盐转化试剂和方法 |
| CN117344010B (zh) * | 2022-06-29 | 2024-04-26 | 广州市基准医疗有限责任公司 | 用于诊断胃癌的dna甲基化生物标记物、试剂盒及用途 |
| WO2024001602A1 (zh) * | 2022-07-01 | 2024-01-04 | 圣湘生物科技股份有限公司 | 一种用于检测胃癌的组合物，试剂盒及其用途 |
| CN116130000B (zh) * | 2022-12-02 | 2023-12-12 | 武汉艾米森生命科技有限公司 | 引物探针序列组合设计方法和装置 |
| CN115976210B (zh) * | 2022-12-08 | 2024-05-28 | 深圳市晋百慧生物有限公司 | 用于胃癌诊断和筛查的试剂盒、方法及其用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104812899A (zh) * | 2012-11-07 | 2015-07-29 | 基因特力株式会社 | 利用胃息肉和胃癌特异性甲基化检测胃息肉和胃癌标记基因的方法 |
| CN106609307A (zh) * | 2017-01-10 | 2017-05-03 | 北京艾克伦医疗科技有限公司 | 基于多个基因诊断胃癌患者的检测试剂盒 |
| CN107904313A (zh) * | 2017-12-29 | 2018-04-13 | 韩林志 | 用于胃癌相关基因Reprimo、RNF180甲基化检测的引物对、试剂盒及方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5541308A (en) * | 1986-11-24 | 1996-07-30 | Gen-Probe Incorporated | Nucleic acid probes for detection and/or quantitation of non-viral organisms |
| US20090298054A1 (en) * | 2004-07-18 | 2009-12-03 | Epigenomics Ag | Epigenetic methods and nucleic acids for the detection of breast cell proliferative disorders |
| CA2629008A1 (en) * | 2005-11-08 | 2007-09-13 | Euclid Diagnostics Llc | Materials and methods for assaying for methylation of cpg islands associated with genes in the evaluation of cancer |
| WO2008122447A2 (en) * | 2007-04-10 | 2008-10-16 | Epigenomics Ag | Dna methylation assay for the diagnosis or prognosis of medical conditions |
| US20100075334A1 (en) * | 2007-04-16 | 2010-03-25 | Yong Sung Kim | Methylation biomarker for early detection of gastric cancer |
| CN104745681B (zh) * | 2014-08-08 | 2018-11-06 | 博尔诚（北京）科技有限公司 | 多元基因组合物及其用途 |
| EP3301194B1 (en) * | 2016-09-30 | 2020-11-04 | National Cancer Center | Method for assisting diagnosis of onset risk of gastric cancer, and artificial dna and kit for diagnosing onset risk of gastric cancer used in the method |
-
2018
- 2018-07-26 US US17/263,291 patent/US20210222260A1/en not_active Abandoned
- 2018-07-26 EP EP18927433.5A patent/EP3828289A4/en active Pending
- 2018-07-26 CN CN201880095978.7A patent/CN112567049A/zh active Pending
- 2018-07-26 WO PCT/CN2018/097297 patent/WO2020019269A1/zh active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104812899A (zh) * | 2012-11-07 | 2015-07-29 | 基因特力株式会社 | 利用胃息肉和胃癌特异性甲基化检测胃息肉和胃癌标记基因的方法 |
| CN106609307A (zh) * | 2017-01-10 | 2017-05-03 | 北京艾克伦医疗科技有限公司 | 基于多个基因诊断胃癌患者的检测试剂盒 |
| CN107904313A (zh) * | 2017-12-29 | 2018-04-13 | 韩林志 | 用于胃癌相关基因Reprimo、RNF180甲基化检测的引物对、试剂盒及方法 |
Non-Patent Citations (3)
| Title |
|---|
| YIPING QU.ET AL: "Gene methylation in gastric cancer", 《CLINICA CHIMICA ACTA》 * |
| 中国卫生检验杂志: "胃癌组织septin 9基因甲基化及其临床意义研究", 《中国卫生检验杂志》 * |
| 曾瑶等: "胃癌中甲基化的作用及相关预后标志物研究进展", 《新医学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113186282A (zh) * | 2021-04-29 | 2021-07-30 | 北京艾克伦医疗科技有限公司 | 鉴定胰腺癌状态的方法和试剂盒 |
| CN113355416A (zh) * | 2021-06-04 | 2021-09-07 | 杭州圣庭医疗科技有限公司 | 一种用于检测胃癌相关基因甲基化的核酸组合物、试剂盒和检测方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3828289A4 (en) | 2022-06-08 |
| EP3828289A1 (en) | 2021-06-02 |
| WO2020019269A1 (zh) | 2020-01-30 |
| US20210222260A1 (en) | 2021-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112567049A (zh) | 鉴定胃癌状态的方法和试剂盒 | |
| CN111630186A (zh) | 鉴定肺癌状态的方法和试剂盒 | |
| CN111630187A (zh) | 鉴定结直肠癌状态的方法和试剂盒 | |
| Resnick et al. | Current and emerging trends in Lynch syndrome identification in women with endometrial cancer | |
| CN109022567A (zh) | 用于鉴定肺结节和/或肺癌状态的试剂盒及其应用 | |
| CN113249477A (zh) | 结直肠癌早期诊断的方法和试剂盒 | |
| WO2016115354A1 (en) | Methods for cancer diagnosis and prognosis | |
| CN108977544A (zh) | 用于鉴定胃癌和/或胃息肉的试剂盒及其应用 | |
| US11111546B2 (en) | 3.4 KB mitochondrial DNA deletion for use in the detection of cancer | |
| CN106399304B (zh) | 一种与乳腺癌相关的snp标记 | |
| CN113699242A (zh) | 检测kras基因突变、adamts1与bnc1甲基化的引物探针，试剂盒与方法 | |
| KR102546357B1 (ko) | 인간 포스포다이에스테라제 4d 변이체 7 발현에 기초한 위험 점수 | |
| CN113186282B (zh) | 鉴定胰腺癌状态的方法和试剂盒 | |
| CN113234821B (zh) | 鉴定食管癌状态的方法和试剂盒 | |
| CA3142438A1 (en) | Dna methylation biomarkers for cancer diagnosing and treatment | |
| US20130288918A1 (en) | Colorectal Cancer Screening Method | |
| CN113897434A (zh) | 鉴定肝癌状态的方法和试剂盒 | |
| CN113278692A (zh) | 鉴定肺结节状态的方法和试剂盒 | |
| CN113234820A (zh) | 鉴定前列腺癌状态的方法和试剂盒 | |
| JP5009289B2 (ja) | Ｍａｌｔリンパ腫の検査方法及びキット | |
| CN114438208A (zh) | 通过外泌体miRNA生物标志物进行肺癌诊断的检测试剂盒和方法 | |
| CN112585282A (zh) | 鉴定乳腺癌状态的方法和试剂盒 | |
| CN113999907A (zh) | 鉴定甲状腺癌状态的方法和试剂盒 | |
| US20220025467A1 (en) | Kcnq1ot1, a new biomarker in peripheral blood for non-invasive detection of gastric cancer (gc) | |
| CN118240939A (zh) | 一种结直肠癌诊断试剂盒、方法及其装置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210326 |